GC patients with HER2 amplification and TP53 mutations had a significant shorter OS compared to patients with HER2 amplification-negative and TP53-mutated tumors (20.4 months vs. 54.04 months, p = 0.03) (Figure 2H). This evidence concerns the gene ERBB2 and gastric cancer.